Semaglutide after effects: what your body is actually going through

The first week: your gut is getting acquainted with a new signal

Picture this: it's a Sunday evening, you've just done your first Wegovy injection, and by Tuesday morning you feel vaguely queasy when you smell breakfast. That's the after effect most people notice first. Semaglutide works partly by slowing how quickly your stomach empties, which is useful for appetite control but can feel unsettling until your gut adapts. Nausea is the most commonly reported effect, affecting a substantial proportion of trial participants, but the critical word is "transient", it tends to peak in the two or three days after injection and then soften.

Alongside nausea, you might notice loose stools or constipation (sometimes alternating), burping, reflux, and a general sense that your digestive system is operating on different timing. These effects are covered in detail in the broader look at how semaglutide changes the body. Eating smaller, lower-fat meals, avoiding alcohol in the early weeks, and staying well hydrated all make the adjustment period more manageable, though your prescriber is the right person to discuss personal strategies with.

Headaches and fatigue in the first week are often secondary: when you're eating and drinking less, your body needs time to recalibrate. They're worth monitoring but are rarely cause for alarm on their own. Injection-site reactions (mild redness, itching, a small lump) can also appear and usually settle within a day or two. Rotating sites (abdomen, thigh, upper arm) helps.

After dose increases: why the pattern can repeat

One thing that catches people off guard is that the after-effect cycle can restart every time the dose goes up. The Wegovy schedule is a gradual staircase (doses increase roughly every four weeks under prescriber guidance) and each step can bring a brief return of nausea or gut sensitivity before your system settles again. This isn't a sign the treatment isn't working; it's the expected pharmacological pattern, documented across the STEP clinical trial programme.

The effects you experience on Wegovy across the titration period are broadly predictable: the stomach symptoms front-load onto the adjustment phase, and for most people the higher maintenance doses are better tolerated than the lower starting ones once the body has adapted. That said, everyone's experience is individual. Some people sail through dose increases; others need to spend longer at a particular dose before moving up. Your prescriber makes that call based on how you're doing, not a fixed calendar.

Fatigue can become more pronounced during titration if appetite suppression is significant and calorie intake drops sharply. Protein adequacy matters here; your prescriber or a dietitian can advise on keeping intake adequate even when hunger is reduced. This is one of the practical reasons clinical supervision isn't just a regulatory formality, it's genuinely useful.

Longer-term effects: what changes as treatment continues

For most people, the more disruptive after effects fade within the first one to three months. What tends to remain (and is the point of the treatment) is a meaningful reduction in appetite and, over time, in body weight. The STEP 1 trial, published in the New England Journal of Medicine, found average weight loss of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside a lifestyle programme. That reduction doesn't happen without the body adjusting to operating on less food, which is itself an after effect of sorts, one most people welcome.

Some effects are less expected. A small number of people notice changes in mood or energy. There are also questions patients sometimes have about whether semaglutide affects blood pressure, the evidence is nuanced and worth understanding if that's relevant to you. Hair thinning, sometimes called telogen effluvium, has been reported by some users; current evidence suggests this is more likely related to rapid weight loss than to the medicine directly, but it's worth flagging to your prescriber if it occurs.

One after effect that warrants specific attention is pancreatitis. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent risk with GLP-1 medicines. Severe stomach pain that radiates to the back (with or without vomiting) needs urgent medical assessment. Don't wait to see if it settles. For a thorough account of less common but serious reactions, the page on semaglutide's adverse effects covers these in clinical detail. You can also read the full adverse-effects breakdown for context on frequency and severity categories.

After stopping: what happens when treatment ends

This is a question our prescribers hear regularly, and the honest answer is that weight regain is common after stopping semaglutide. The treatment works while it's active in the body; once discontinued, the appetite-suppressing signal fades and hunger tends to return. Trial follow-up data consistently show that a proportion of weight lost is regained within months of stopping. That's not a failure, it reflects the biology of a chronic condition.

The after effects of discontinuation are usually the reverse of the treatment effects: appetite returns, sometimes more strongly than before. There are no serious withdrawal effects in the clinical sense; semaglutide doesn't create physical dependence. But the return of hunger can feel abrupt if people aren't prepared for it. If you're considering stopping, or wondering about other weight management options, that conversation belongs with your prescriber, who can plan a sensible approach, including whether continuing at a lower maintenance dose makes sense.

Understanding the cost context of longer-term treatment is worth doing early. A clear breakdown of what private treatment involves is available on the Wegovy cost comparison page, which explains what legitimate treatment pricing includes beyond the medicine itself. For anyone considering starting treatment or transferring from another provider, checking your eligibility with our prescribers is a sensible first step, no obligation, no pressure, same-day clinical review once your answers are in.